Pharmaceutical M&A deals in 2010

Company

Partner

Deal value $ 
 

Completed
 

Abbott Labs (US)

Facet Biotech (US)

$722.0 million

Apr 2010

Abbott Labs (US)

Piramal (India)
Domestic formulation business

$3.72 billion

June 2010

Actavis (Iceland)

Deustche Bank (Germany)

Undisclosed

Oct 3020

Anika Thera (US)

Fidia Advanced Polymers
(from Italy’s Fidia group)

$17.1 million

Jan 2010

Ares Life Sci (Swiss)

Stallergenes (France)

$1.0 billion

Dec 2011

Arseus (Belgium)

Gallipot (US)

$12.5 million

May 2010

Aspen (Sth Africa)

Sigma Pharma (Australia)
(Revised deal for just Pharma Division)

$807 million)

Jan 2011

Astellas (Japan)

OSI Pharma (US)

$3.5 billion

June 2010

Axcan (US)

Eurand (Netherlands)

$583.0 million

2ndQ 2011

Baxter Int (US)

ApaTech (UK)

$330 million

Apr 1010

Biocon (India)

Biocon Biopharma (Cuba)
(49% stake in JV held by CIMAB)

Undisclosed

Apr 2010

Biogen Idec (US)

Unit of Neurimmune (Swiss)
($32.5 million upfront;
rest contingent payments)

$427.5 million

Dec 2010

BioMarin  Pharma (US)

ZyStor Therapeutics (US)

115.0 million

Aug 2010

BioMerieux (France)

Knome (US)
(10% stake)

$5.0 million

Apr 2010

Biovail (US)

Valeant (Canada)

$3.2 billion

Sept 2010

Boehringer Ingelheim  (Germany)

SSP (Japan)
(remaining 40%)

$365.0 million

Apr 2010

Bristol-Myers Squibb (US)

ZymoGenetics (US)

$855.0 million

Oct 2010

BTG (UK)

Biocompatibles (UK)

$258.4 million

TBC

Cambrex Corp (US)

Zenara Pharma (India)
51% stake
(Option to acquire rest of firm in 2016)

$20.0 million

Nov 2010

Cardinal Health (US)

Zuellig Pharma (China)

$470.0 million

Nov 2010

Conatus Pharma (US)

Indun Pharma (a Pfizer unit)

Undisclosed

Aug 2010

Celgene (US)

Abraxis BioScience (US)

£2.9 billion

Oct 2010

Cephalon (US)

Mepha AG (Swiss)

$590.0 million

Apr 2010

Cephalon (US)

Ception Thera (US)
(plus $100 million upfront)

$250.0 million

Apr 2010

Cephalon (US)

BioAssets Dev Corp (US)
($30 million paid as option fee)

$42.5 million

Nov 2010

Cephalon (US)

Mesoblast (Australia) 20% stake

$220.0 million

Dec 2010

Cipla (India)

Minority stakes in an Indian and a Hong Kong biotech firm

$65 million

June 2019

Cipla (India)

Meditab (India)

$28.5 million

2010

Daiichi Sankyo (Japan)

PharmaForce (US)

Undisclosed

Jan 2010

Daiichi Sankyo (Japan)

Roxro Pharma (US)

Undisclosed

Dec 2010

Emergent BioSolutions (US)

Trubion Pharma (US)

$135.5 million

Oct 2010

Endo Pharma (US)

HealthTronics (US)

$233.0 million

July 2010

Endo Pharma (US)

Penwest Pharma (US)

$144.0 million

Nov 2010

Endo Pharma (US)

Qualitest (US)

$1.2 billion

Dec 2010

Euthymics (US)

DOV Pharma (US)

Undisclosed

July 2010

Evotec (Germany)

DeveloGen (Germany)

$17.7 million

Sept 2010

Galapagos (Belgium)

Argenta (UK)

$22.7 million

Apr 2010

Gedeon Richter (Hungary)

PregLem (Switzerland)

$461.0 million

Oct 2010

Gilead Sciences (US)

CGL Pharma (US)

$120.0 million

Sept 2010

Gilead Sciences (US)

Arresto Bioscience (US)

$225.0 million

1stQ 2011

GlaxoSmithKline (UK)

Lab Phoenix (Argentine)

$253.0 million

June 2010

GlaxoSmithKline (UK)

Amicus (US) 19.9% stake

$31.0 million

Oct 2010

GlaxoSmithKline (UK)

Theravance (US)
(Stake increased to 19%)

$129.4 million

Dec 2010

GlaxoSmithKline (UK)

Nanjing MeiRui (China)

$70.0 million

TBC

GlaxoSmithKline (UK)

Maxinutrition (UK)

$257.0 million

TBC

Grifols (Spain)

Talecris Bio (US)

$3.4 billion

TBC

HELM AG (Germany)

Amarin Technologies (Argentina)
(30% stake in the firm)

Undisclosed

Sept 2010

Hikma (Jordon)

Baxter injectable generics bus

$112.0 million

Nov 2010 

Hospira (US)

Javelin Pharma (US)

$141.0 million

July 2010

Invida (Singapore)

MUGI (Indonesia) 70%

Undisclosed

May 2010

Ipsen (France)

Inspiration Biopharma (US)
(Initial stake of 20%, poss reaching 47% or 100%) Added to stake to total 34% in Nov

$85 million

$50 million

Jan 2010

Nov 2010

Johnson & Johnson (US)

RespiVert (UK)

$102.5 million

June 2010

Johnson & Johnson (US)

Crucell (Netherlands)
(remaining 80.1% not already held)

$2.3 billion

TBC

LFB Biotechnologies (Fr)

GTC Biotherapeutics (US)

$18.3 million

Dec 2010

LabCorp (US)

Genzyme Genetics business
of Genzyme (US)

$925.0 million

Dec 2010

Lonza (Switzerland)

Vivante GMPSolutions (US)

Undisclosed

Aug 2010

Lexicon Pharma (US)

Symphony Icon (US)

$90.0 million

Aug 2010

Life Technologies (US)

GENEART (Germany)

$75.8 million

Apr 2010

Life Technologies (US)

Ion Torrent (US)
(Further $350 million on milestones)

$375.0 million

Oct 2010

Lilly, Eli (US)

Pfizer (US) European animal
health assets

Undisclosed

2010

Lilly, Eli (US)

Alnara Pharma (US)

Undisclosed

July 2010

Lilly, Eli (US)

Avid Radiopharmaceutical (US)
Further $500 million dependent of achievement of milestones

$300.0 million

Dec 2010

MDRNA (US)

Cequent Pharma (US)
Renamed as Marina Biotech

$46.0 million
(Stock deal)

Aug 2010

Manhattan Pharma (US)

Ariston Pharma (US)

Stock deal

Mar 2010

McKesson (US)

US Oncology (US)

$2.16 billion

Dec 2010

Meda AB (Sweden)

Alaven Pharma (US)

$350.0 million

Oct 2010

Merck & Co (US)

SmartCells (US)
Deal based on milstones

$500.0 million

TBC

Merck KGaA (Germany)

Millipore (US)

$7.2 billion

July 2010

Merz Pharma (Germany)

BioForm Med (US)

$253 million

Feb 2010

Mesoblast (Australia)

Angioblast (US)

$30.0 million

Dec 2010

Minapharm (Egypt)

ProBioGen (Germany)
(95% stake)

$36.8 million

June 2010

MorphoSys (Germany)

Sloning BioTechnology (Germany)

$26.1 million

Oct 2010

Mylan (US)

Bioniche Pharma (Ireland)

$550.0 million

Sept 2010

NeoPharm (US)

Insys Therapeutics (US)

Undisclosed

Nov 2010

Norgine (UK)

ProStrakan (UK)
(12.6% stake)

$3.9 million

Nov 2010

NovAliX (France)

Graffinity Pharma (Germany)

Undisclosed

Nov 2010

NovAliX (France)

NMRTec (France)
(Majority stake in the firm)

Undisclosed

Jan 2010

Novartis (Swiss)

Alcon (Swiss)
bringing majority stake bought from Nestle to 77%;
set to buy remaining 23% from Alcon shareholders

$28.1 billion

Sept 20

Novartis (Swiss)

Chiron Behring Vacc (India)
(acquires Sanofi-Aventis 49% stake in JV)

$22.4 million

Dec 2010

Novartis/Sandoz (Swiss)

Oriel Therapeutics (US)

Undisclosed

2010

Nycomed (Swiss)

Guangdon Techpool (China)
51.34% stake in the company

$210.0 million

Nov 2010

Orchid Chem & Pharma
(India)

Karalex Pharma (USA)

Undisclosed

June 2010

Pfizer (US)

FoldRx (US)

Undisclosed

Oct 2010

Pfizer (US)

King Pharmaceuticals (US)

$3.6 billion

TBC

Pfizer (US)

Lab Teuto Brasileiro (Brazil)
40% stake that can be increased in 2015

$240.0 million

TBC

Phadia (Sweden)

Nanjing Wei Kang (China)

Undisclosed

Dec 2010

Piramal (India)

Bharat Serums (inj anesthetics business)

c.$4.0 million

2010

Proximagen (UK)

Minster Pharma (UK)

$6.9 million

Mar 2010

Radient Pharma (US)

Provista Diagnostics (US)

Undisclosed

Dec 2010

Ramius and Royalty

Cypress Biosciences (US)

$255.0 million

Jan 2011

Pharma (US)

Ranbaxy (India)

Biovel (India)

Undisclosed

2010

Recordati (Italy)

ArtMed Int (Romania)

$1.5 million

June 2010

Roche (Swiss)

Medingo (Israel)

$160.0 million

2010

Sanofi-Aventis (France)

Merck & Co (US) Animal Health
(Merger of animal health)

Undisclosed

July 2010

Sanofi-Aventis (France)

TargeGen (US)
($75 million upfront)

$560.0 million

July 2010

Sanofi-Aventis (France)

Genzyme (US)

$18.5 billion

TBC

Sanofi-Aventis (France)

BMP Suntone (China)
(Consumer health care)

$520.0 million

TBC

Santarus (US)

Covella (US)

$1.8 million

Sept 2010

Sekisui Chem (Japan)

Genzyme (US) Diagnostics unit

$265.0 million

TBC

Shanghai Pharma (China)

China Health System (China)
55.45% majority stake

$603.0 million

TBC

Shire (UK)

Movetis (Belgian)

$558.0 million

Nov 2010

Sihuan Pharma (China)

Dupromise (Russia)

$360.7 million

TBC

Sosei (Japan)

Activus Pharma (Japan)
Stock transaction

Undisclosed

2010

Sun Pharma (India)

Taro Pharma (Israel) 78% stake

$454.0 million

Sept 2010

Sun Pharma (India)

Caraco Pharma Labs (US)

$188.0 million

Dec 2010

Teva (Israel)

Taisho Pharma Ind (Japan)
(To take 66.7% interest in joint venture with Kowa)

Undisclosed

2010 

Teva (Israel)

Ratiopharm (German)

$4.95 billion

Aug 2010

Teva (Israel)

Andromeda Biotech (Israel)
Increased investment in the firm

$11.9 million

June 2010

Teva (Israel)

Theramex (Switzerland)
(Women’s health unit of Merck KGaA)

$368.0 million

Jan 2011

UCB (Belgium)

WILEX AG (Germany)
Increased stake to 18%

Undisclosed

June 2010

Valeant (US)

Inst Terapeutico Delta (Brazil)

$28.0 million

Mar 2010

Valeant (US)

Unnamed Brazilian firm

$56.0 million

Apr 2010

Valeant (US)

Vital Sciences (Canada)

$10.3 million

Apr 2010

Valeant (US)

Aton Pharma (US)

$318 million

May 2010

VaxGen (US)

diaDexus (US) Stock deal

Undisclosed

June 2010

Victory Pharma (US)

MiddleBrook Pharma (US)
(Acquired assets of the firm)

Undisclosed

Aug 2010